BACKGROUND: Sarcomas are rare mesenchymally derived tumors for which there are limited treatment options. This paper discusses the current therapeutic potential of directed tyrosine kinase inhibitors (TKIs) in sarcoma. METHODS: The authors review antibody-based strategies and small molecular inhibitors of TKIs, with specific emphasis placed on the potential use of these targeted agents as therapeutic options for the treatment of sarcomas that are not gastrointestinal stromal tumors. RESULTS: Many TKs have been shown to be mutated or overexpressed in human sarcoma tumors and cell lines and may serve as potential targets for promising new sarcoma therapies. Furthermore, the novel mechanism of targeting TKs may complement the antitumor activity of existing sarcoma treatment options. CONCLUSIONS: TKIs such as imatinib, sunitinib, and sorefanib are promising new therapeutic options for the management of patients with soft tissue sarcoma.
BACKGROUND:Sarcomas are rare mesenchymally derived tumors for which there are limited treatment options. This paper discusses the current therapeutic potential of directed tyrosine kinase inhibitors (TKIs) in sarcoma. METHODS: The authors review antibody-based strategies and small molecular inhibitors of TKIs, with specific emphasis placed on the potential use of these targeted agents as therapeutic options for the treatment of sarcomas that are not gastrointestinal stromal tumors. RESULTS: Many TKs have been shown to be mutated or overexpressed in humansarcoma tumors and cell lines and may serve as potential targets for promising new sarcoma therapies. Furthermore, the novel mechanism of targeting TKs may complement the antitumor activity of existing sarcoma treatment options. CONCLUSIONS: TKIs such as imatinib, sunitinib, and sorefanib are promising new therapeutic options for the management of patients with soft tissue sarcoma.
Authors: Silvia Calabuig-Fariñas; José Antonio López-Guerrero; M Jesús Nicolau Ribera; Samuel Navarro; David Ramos; Antonio Pellín; Antonio Llombart-Bosch Journal: Virchows Arch Date: 2009-02-03 Impact factor: 4.064
Authors: Parag P Patwardhan; Oliver Surriga; Michael J Beckman; Elisa de Stanchina; Ronald P Dematteo; William D Tap; Gary K Schwartz Journal: Clin Cancer Res Date: 2014-04-09 Impact factor: 12.531
Authors: Yun Bai; Jiannong Li; Bin Fang; Arthur Edwards; Guolin Zhang; Marilyn Bui; Steven Eschrich; Soner Altiok; John Koomen; Eric B Haura Journal: Cancer Res Date: 2012-03-29 Impact factor: 12.701
Authors: A C M van de Luijtgaarden; J W J de Rooy; L F de Geus-Oei; W T A van der Graaf; W J G Oyen Journal: Cancer Imaging Date: 2008-10-04 Impact factor: 3.909